GoKawiilAnthropic-backed Claude experiment fails to produce real scorpion antivenom
Investment research firm Citrini Research collaborated with Anthropic, testing an unreleased version of Claude to see if it could design a scorpion antivenom from scratch. Experts told The Verge the AI generated only preliminary leads, not a viable drug candidate, and Citrini itself admitted none of its team had biology expertise. Anthropic reportedly lifted Claude's biosecurity restrictions and gave Citrini access to the advanced model for the project.
GoKawiil's interpretation of the reporting above, not reported fact.
The episode suggests that claims about AI's readiness to overhaul drug discovery may outpace its actual scientific capability, especially when non-experts drive the experiment. Anthropic's willingness to loosen safety guardrails for a media-friendly stunt ahead of its reported IPO raises questions about how AI labs balance publicity with caution around biosecurity-sensitive research. Citrini's history of viral, attention-grabbing narratives adds reason for skepticism about how the results were framed.
- Claude did not create a working scorpion antivenom despite the hype.
- Anthropic disabled biosecurity restrictions to let Citrini access an unreleased model.
- Citrini Research has a history of producing viral but speculative AI-related narratives.
Source: theverge.com — Robert Hart, 2026-10-22
Published there as: “Claude did not invent scorpion antivenom”
Read the original report → The summary and analysis above are GoKawiil's own, written from reporting by the source above. Facts and quotes belong to the original publisher.